<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40364">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02123823</url>
  </required_header>
  <id_info>
    <org_study_id>1280.4</org_study_id>
    <secondary_id>2013-001110-15</secondary_id>
    <nct_id>NCT02123823</nct_id>
  </id_info>
  <brief_title>BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer</brief_title>
  <official_title>A Phase Ib/II Randomized Study of BI 836845 in Combination With Exemestane and Everolimus Versus Exemestane and Everolimus Alone in Women With Locally Advanced or Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Belgium: Federal Agency for Medicinal and Health Products</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Ireland: Irish Medicines Board</authority>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <authority>Netherlands: Central Committee Research Involving Human Subjects</authority>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <authority>Sweden: Medical Products Agency</authority>
    <authority>Taiwan : Food and Drug Administration</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase Ib / II study to determine the Maximum Tolerated Dose  and Recommended Phase II Dose,
      and to evaluate the safety and antitumour activity, of BI 836845 and everolimus in
      combination with exemestane  in women with HR+/HER2- advanced breast cancer
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>up to 11 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>occurrence of Dose Limiting Toxicity (DLT) - phase I part</measure>
    <time_frame>up to 28 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP), defined as the duration of time from the date of C1V1until the date of the first objective tumor progression</measure>
    <time_frame>up to 11 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response (OR), defined as complete response (CR) or partial response (PR) (CR + PR)</measure>
    <time_frame>up to 11 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to objective response</measure>
    <time_frame>up to 11 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of objective response</measure>
    <time_frame>up to 11 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit (CB), defined as best overall response of complete response (CR) or partial response (PR), or stable disease (SD) &gt;=6 months, or Non-CR/Non-PD for &gt;=6 months (CR + PR + SD6m + Non-CR/Non-PD6m)</measure>
    <time_frame>up to 11 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of clinical benefit</measure>
    <time_frame>up to 11 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">198</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Everolimus 10mg + Exemestane 25mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Phase II - Daily everolimus oral administration 10mg + daily exemestane 25 mg orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI836845 + Everolimus + Exemestane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase II - BI 836845 recommended dose will be administered intravenously once every week, in addition to daily everolimus (oral administration at recommended dose) + daily exemestane 25 mg orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PhI - BI836845 + Everolimus + Exemestane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase I - Dose escalation (24-48 patients) BI 836845 low or high dose, Everolimus 5mg, 7,5mg or 10 mg and Exemestane 25mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>10mg dose</description>
    <arm_group_label>Everolimus 10mg + Exemestane 25mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>at recommended dose as per Phase I data</description>
    <arm_group_label>BI836845 + Everolimus + Exemestane</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Dose escalation (24-48 patients) in Phase I. 3 dose levels depending on the dose cohort explored: 5mg, 7,5mg and 10mg</description>
    <arm_group_label>PhI - BI836845 + Everolimus + Exemestane</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exemestane</intervention_name>
    <description>Fixed dose at 25mg</description>
    <arm_group_label>PhI - BI836845 + Everolimus + Exemestane</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 836845</intervention_name>
    <description>Human monoclonal antibody at recommended dose as per Phase I data</description>
    <arm_group_label>BI836845 + Everolimus + Exemestane</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 836845</intervention_name>
    <description>Human monoclonal antibody. Dose escalation (24-48 patients) in Phase I.  2 dose levels (high or low) depending on the dose cohort explored</description>
    <arm_group_label>PhI - BI836845 + Everolimus + Exemestane</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exemestane</intervention_name>
    <description>Fixed dose at 25mg</description>
    <arm_group_label>BI836845 + Everolimus + Exemestane</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exemestane</intervention_name>
    <description>Fixed dose at 25mg</description>
    <arm_group_label>Everolimus 10mg + Exemestane 25mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Histologically-confirmed locally advanced (aBC) or metastatic breast cancer (mBC) not
             deemed amenable to curative surgery or curative radiation therapy

          -  Tumors are positive for estrogen-receptor (ER) and/or progesterone receptor (PgR).

          -  Tumors must be negative for HER2 per local lab testing.

          -  Must have adequate archival tumor tissue from surgery or biopsy.

          -  Postmenopausal women.

          -  Objective evidence of recurrence or progressive disease on or after the last line of
             systemic therapy for breast cancer prior to study entry

          -  The patient is disease refractory to non-steroidal aromatase inhibitor (letrozole
             and/or anastrozole)

          -  Patients must have Measurable lesion according to RECIST version 1.1 or Bone lesions
             only: lytic or mixed (lytic + sclerotic) in the absence of measurable lesion as
             defined above

          -  Eastern Cooperative Oncology Group  performance score &lt;= 2.

          -  Life expectancy of &gt;= 6 months in the opinion of the investigator

          -  Fasting plasma glucose &lt; 8.9 mmol/L (&lt; 160 mg/dL) and HbA1c &lt; 8.0%

          -  Adequate organ function

          -  Recovered from any previous therapy related toxicity to &lt;= Grade 1 at study entry
             (except for stable sensory neuropathy &lt;=Grade 2 and alopecia)

          -  Written informed consent that is consistent with ICH-GCP guidelines and local
             regulations

        Inclusion criteria for the biopsy substudy are identical to the main study of the phase II
        part except for the following two inclusion criteria:

          -  Fresh tumor biopsy should be taken when deemed safe and feasible by the investigator
             and upon informed consent by the patient. Bone lesion is not recommended for biopsy

          -  Patients eligible to undergo tumor biopsy should have normal coagulation parameters
             (INR and PTT within normal range)

        Exclusion criteria:

          -  Previous treatment with agents targeting on IGF pathway, phosphoinositide 3-kinase
             (PI3K) signaling pathway, protein kinase B (AKT), or mammalian target of rapamycin
             (mTOR) pathways

          -  Prior treatment with exemestane

          -  Known hypersensitivity to monoclonal antibody, mTOR inhibitors (e.g. sirolimus), or
             to the excipients of any study drugs

          -  Ovarian suppression by ovarian radiation or treatment with a luteinizing
             hormone-releasing hormone (LH-RH) agonist

          -  Less than one week after receiving immunization with attenuated live vaccines prior
             to study treatment

          -  Radiotherapy within 4 weeks prior to run-in treatment, except in case of localized
             radiotherapy for analgesic purpose or for lytic lesions at risk of fracture which can
             then be completed within two weeks prior to study treatment

          -  Chemotherapy, biological therapy (other than bevacizumab), immunotherapy or
             investigational agents within 5 half-life of the drug or within two weeks prior to
             the start of study treatment, whichever is longer; bevacizumab treatment within 4
             weeks prior to start of study treatment

          -  Hormonal treatment for breast cancer within 2 weeks prior to start of study treatment

          -  Major surgery in the judgement of the investigator within 4 weeks before starting
             study treatment or scheduled for surgery during the projected course of the study

          -  Patients receiving concomitant immunosuppressive agents or chronic corticosteroids
             use except Topical applications, inhaled sprays, eye drops or local injections or
             Patients on stable low dose of corticosteroids for at least two weeks before study
             entry

          -  Chronic hepatitis B infection, chronic hepatitis C infection and/or known HIV carrier

          -  QTcF prolongation &gt; 470 ms or QT prolongation deemed clinically relevant by the
             investigator

          -  Disease that is considered by the investigator to be rapidly progressing or life
             threatening such as extensive symptomatic visceral disease including hepatic
             involvement and pulmonary lymphangitic spread of tumor

          -  History of brain or other CNS metastases

          -  Bilateral diffuse lymphangitic carcinomatosis

          -  Hypokalemia of Grade &gt;1

          -  History of another primary malignancy within 5 years, with the exception of
             adequately treated in-situ carcinoma of the cervix, uteri, basal or squamous cell
             carcinoma or non-melanomatous skin cancer

          -  Family history of long QT syndrome

          -  Any concomitant serious illness or organ system dysfunction which in the opinion of
             the investigator would either compromise patient safety or interfere with the
             evaluation of the safety and anti-tumor activity of the test drug(s)

          -  Patients being treated with drugs recognized being strong or moderate CYP3A4 and/or
             PgP inhibitors and/or strong CYP3A4 inducers within 2 weeks prior to study entry

          -  Patients received more than two lines of chemotherapy for locally advanced or
             metastatic breast cancer (For the Phase II: more than one line)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boehringer Ingelheim Call Center</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>1280.4.3202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1280.4.3201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1280.4.3301 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1280.4.3101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 24, 2014</lastchanged_date>
  <firstreceived_date>April 22, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Exemestane</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
